litlas
ログインアカウント作成

Scott M. Wasserman

2002–2020 年に発表

59
論文数
24,434
被引用数
57
h 指数
59
i10 指数

被引用数

Scott M. Wasserman の年別被引用数1969 年: 被引用 5 件1985 年: 被引用 1 件1997 年: 被引用 1 件1998 年: 被引用 1 件2003 年: 被引用 4 件2004 年: 被引用 20 件2005 年: 被引用 29 件2006 年: 被引用 12 件2007 年: 被引用 7 件2008 年: 被引用 32 件2009 年: 被引用 28 件2010 年: 被引用 14 件2011 年: 被引用 25 件2012 年: 被引用 30 件2013 年: 被引用 139 件2014 年: 被引用 222 件2015 年: 被引用 377 件2016 年: 被引用 323 件2017 年: 被引用 489 件2018 年: 被引用 447 件2019 年: 被引用 1,207 件2020 年: 被引用 1,112 件2021 年: 被引用 914 件2022 年: 被引用 803 件2023 年: 被引用 610 件2024 年: 被引用 950 件2025 年: 被引用 524 件2026 年: 被引用 33 件1970〜1984 年は被引用が無いため表示していません1986〜1996 年は被引用が無いため表示していません1999〜2002 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,079 件、この内訳の 20.7%イギリス: 引用元論文 756 件、この内訳の 7.5%中国: 引用元論文 583 件、この内訳の 5.8%イタリア: 引用元論文 544 件、この内訳の 5.4%カナダ: 引用元論文 499 件、この内訳の 5%ドイツ: 引用元論文 483 件、この内訳の 4.8%オランダ: 引用元論文 434 件、この内訳の 4.3%オーストラリア: 引用元論文 387 件、この内訳の 3.8%フランス: 引用元論文 351 件、この内訳の 3.5%スペイン: 引用元論文 277 件、この内訳の 2.7%スイス: 引用元論文 259 件、この内訳の 2.6%日本: 引用元論文 252 件、この内訳の 2.5%
0%20.7%その他 31.4%

機関

分野

  • Medicine81%
  • Biochemistry, Genetics and Molecular Biology12.2%
  • Immunology and Microbiology3.2%
  • Economics, Econometrics and Finance0.6%
  • Computer Science0.5%
  • Neuroscience0.4%
  • その他2.1%

トピック

  • Lipoproteins and Cardiovascular Health18.7%
  • Diabetes, Cardiovascular Risks, and Lipoproteins6.4%
  • Atherosclerosis and Cardiovascular Diseases4.9%
  • Cancer, Lipids, and Metabolism2.7%
  • Bone health and osteoporosis research2.2%
  • Health Systems, Economic Evaluations, Quality of Life1.9%
  • その他63.2%

共著者

全論文

検索で開く
  1. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

    著者: Marc S. Sabatine, Robert P. Giugliano, Anthony Keech, Narimon Honarpour, Stephen D. Wiviott, Sabina A. Murphy, Julia Kuder, Huei Wang, Thomas Liu, Scott M. Wasserman, Peter Sever, Terje R. Pedersen - New England Journal of Medicine 2017 被引用: 5,987

  2. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk

    著者: Michelle L. O’Donoghue, Sergio Fazio, Robert P. Giugliano, Erik S.G. Stroes, Estella Kanevsky, Ioanna Gouni‐Berthold, KyungAh Im, Armando Lira Pineda, Scott M. Wasserman, R Češka, М. В. Ежов, J. Wouter Jukema, Henrik Kjærulf Jensen, S. Lale Tokgözoğlu, François Mach, Kurt Huber, Peter Sever, Anthony Keech, Terje R. Pedersen, Marc S. Sabatine - Circulation 2019 被引用: 948

  3. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients

    著者: Stephen J. Nicholls, Rishi Puri, Todd J. Anderson, Christie M. Ballantyne, Leslie Cho, John J.P. Kastelein, Wolfgang Köenig, Ransi Somaratne, Helina Kassahun, Jingyuan Yang, Scott M. Wasserman, Robert C. Scott, Imre Ungi, Jakub Podolec, Antonius Oude Ophuis, Jan H. Cornel, Marilyn Borgman, Danielle M. Brennan, Steven E. Nissen - JAMA 2016 被引用: 1,154

  4. Romosozumab in Postmenopausal Women with Low Bone Mineral Density

    著者: Michael R. McClung, Andreas Grauer, Steven Boonen, Michael A. Bolognese, Jacques P. Brown, Adolfo Díez‐Pérez, Bente Langdahl, Jean‐Yves Reginster, José Zanchetta, Scott M. Wasserman, Leonid Katz, Judy Maddox, Yuching Yang, Cesar Libanati, Henry G. Bone - New England Journal of Medicine 2014 被引用: 1,235

  5. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

    著者: Robert P. Giugliano, Terje R. Pedersen, Jeong-Gun Park, Gaetano Maria De Ferrari, Zbigniew Gaciong, R Češka, Kálmán Tóth, Ioanna Gouni‐Berthold, José López‐Miranda, François Schiele, François Mach, Brian R. Ott, Estella Kanevsky, Armando Lira Pineda, Ransi Somaratne, Scott M. Wasserman, Anthony Keech, Peter S. Sever, Marc S. Sabatine - The Lancet 2017 被引用: 677

  6. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

    著者: Marc S. Sabatine, Robert P. Giugliano, Stephen D. Wiviott, Frederick J. Raal, Dirk Blom, Jennifer G. Robinson, Christie M. Ballantyne, Ransi Somaratne, Jason C. Legg, Scott M. Wasserman, Robert C. Scott, Michael J. Koren, Evan A. Stein - New England Journal of Medicine 2015 被引用: 1,495

  7. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

    著者: Frederick J. Raal, Evan A. Stein, Robert Dufour, Traci Turner, Fernando Civeira, Lesley Burgess, Gisle Langslet, Russell Scott, Anders Olsson, David Sullivan, G. Kees Hovingh, Bertrand Cariou, Ioanna Gouni‐Berthold, Ransi Somaratne, Ian Bridges, Robert C. Scott, Scott M. Wasserman, Daniel Gaudet - The Lancet 2014 被引用: 751

  8. A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

    著者: Dirk Blom, Tomas Hala, Michael A. Bolognese, Michael Lillestol, Phillip D. Toth, Lesley Burgess, R Češka, Eli M. Roth, Michael J. Koren, Christie M. Ballantyne, Maria Laura Monsalvo, Kate Tsirtsonis, Jae Bum Kim, Robert C. Scott, Scott M. Wasserman, Evan A. Stein - New England Journal of Medicine 2014 被引用: 713

  9. Cognitive Function in a Randomized Trial of Evolocumab

    著者: Robert P. Giugliano, François Mach, Kenton H. Zavitz, Christopher E. Kurtz, Kyungah Im, Estella Kanevsky, Jingjing Schneider, Huei Wang, Anthony Keech, Terje R. Pedersen, Marc S. Sabatine, Peter S. Sever, Jennifer G. Robinson, Narimon Honarpour, Scott M. Wasserman, Brian R. Ott - New England Journal of Medicine 2017 被引用: 482

  10. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance

    著者: Steven E. Nissen, Erik S.G. Stroes, Ricardo E. Dent‐Acosta, Robert S. Rosenson, Sam J. Lehman, Naveed Sattar, David Preiss, Éric Bruckert, R Češka, Norman E. Lepor, Christie M. Ballantyne, Ioanna Gouni-Berthold, Mary Elliott, Danielle M. Brennan, Scott M. Wasserman, Ransi Somaratne, Rob Scott, Evan A. Stein, for the GAUSS-3 Investigators - JAMA 2016 被引用: 511

  11. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

    著者: Frederick J. Raal, Narimon Honarpour, Dirk Blom, G. Kees Hovingh, Feng Xu, Robert C. Scott, Scott M. Wasserman, Evan A. Stein - The Lancet 2014 被引用: 727

  12. Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

    著者: Robert P. Giugliano, Terje R. Pedersen, Jeffrey L. Saver, Peter S. Sever, Anthony Keech, Erin A. Bohula, Sabina A. Murphy, Scott M. Wasserman, Narimon Honarpour, Huei Wang, Armando Lira Pineda, Marc S. Sabatine, on behalf of the FOURIER Investigators - Stroke 2020 被引用: 182

  13. Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial

    著者: David M. Charytan, Marc S. Sabatine, Terje R. Pedersen, KyungAh Im, Jeong‐Gun Park, Armando Lira Pineda, Scott M. Wasserman, Prakash Deedwania, Anders Olsson, Peter Sever, Anthony Keech, Robert P. Giugliano - Journal of the American College of Cardiology 2019 被引用: 203

  14. Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia

    著者: Jennifer G. Robinson, Bettina S. Nedergaard, William J. Rogers, Jonathan Fialkow, Joel M. Neutel, David Ramstad, Ransi Somaratne, Jason C. Legg, Patric Nelson, Robert C. Scott, Scott M. Wasserman, Robert Weiss - JAMA 2014 被引用: 501

  15. Anti-PCSK9 Monotherapy for Hypercholesterolemia

    著者: Michael J. Koren, Pernille Lundqvist, Michael A. Bolognese, Joel M. Neutel, Maria Laura Monsalvo, Jingyuan Yang, Jae B. Kim, Robert C. Scott, Scott M. Wasserman, Harold Bays - Journal of the American College of Cardiology 2014 被引用: 407

  16. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor

    著者: Sreeneeranj Kasichayanula, Anita Grover, Maurice G. Emery, Megan Gibbs, Ransi Somaratne, Scott M. Wasserman, John P. Gibbs - Clinical Pharmacokinetics 2018 被引用: 131

  17. Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

    著者: Erik S.G. Stroes, David Colquhoun, David Sullivan, Fernando Civeira, Robert S. Rosenson, Gerald F. Watts, Éric Bruckert, Leslie Cho, Ricardo Dent, Beat Knüsel, Allen Xue, Robert C. Scott, Scott M. Wasserman, Michael Rocco - Journal of the American College of Cardiology 2014 被引用: 527

  18. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment

    著者: Lotte C.A. Stiekema, Erik S.G. Stroes, Simone L. Verweij, Helina Kassahun, Lisa Chen, Scott M. Wasserman, Marc S. Sabatine, Venkatesh Mani, Zahi A. Fayad - European Heart Journal 2018 被引用: 136

  19. Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia

    著者: Evan A. Stein, Narimon Honarpour, Scott M. Wasserman, Feng Xu, Robert C. Scott, Frederick J. Raal - Circulation 2013 被引用: 330

  20. Effect of Evolocumab on Coronary Plaque Composition

    著者: Stephen J. Nicholls, Rishi Puri, Todd J. Anderson, Christie M. Ballantyne, Leslie Cho, John J.P. Kastelein, Wolfgang Köenig, Ransi Somaratne, Helina Kassahun, Jingyuan Yang, Scott M. Wasserman, Satoshi Honda, Daisuke Shishikura, D. Scherer, Marilyn Borgman, Danielle M. Brennan, Kathy Wolski, Steven E. Nissen - Journal of the American College of Cardiology 2018 被引用: 142

  21. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

    著者: Robert P. Giugliano, Nihar R. Desai, Payal Kohli, William J. Rogers, Ransi Somaratne, Fannie Huang, Thomas Liu, Satishkumar Mohanavelu, Elaine Hoffman, Shannon T McDonald, Timothy E Abrahamsen, Scott M. Wasserman, Robert C. Scott, Marc S. Sabatine - The Lancet 2012 被引用: 424

  22. Cardiovascular Drug Development

    著者: Christopher B. Fordyce, Matthew T. Roe, Tariq Ahmad, Peter Libby, Jeffrey Borer, William R. Hiatt, Michael R. Bristow, Milton Packer, Scott M. Wasserman, Ned Braunstein, Bertram Pitt, David L. DeMets, Katharine Cooper‐Arnold, Paul W. Armstrong, Scott D. Berkowitz, Robert C. Scott, Jayne Prats, Zorina S. Galis, Norman Stockbridge, Eric D. Peterson, Robert M. Califf - Journal of the American College of Cardiology 2015 被引用: 204

  23. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics

    著者: Gerald F. Watts, Dick C. Chan, Ransi Somaratne, Scott M. Wasserman, Robert C. Scott, Santica M. Marcovina, P. Hugh R. Barrett - European Heart Journal 2018 被引用: 147

  24. Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia

    著者: Michael J. Koren, Marc S. Sabatine, Robert P. Giugliano, Gisle Langslet, Stephen D. Wiviott, Andrea Ruzza, Yuhui Ma, Andrew Hamer, Scott M. Wasserman, Frederick J. Raal - Journal of the American College of Cardiology 2019 被引用: 146